Curetopia, a Biotech DAO, leverages decentralized science to speed up uncommon illness research
Zug, Switzerland, twentieth March 2025, ZEX PR WIRE, In a groundbreaking achievement, Curetopia, the primary Biotech Decentralized Autonomous Group (DAO) constructed natively on the Solana blockchain, raised $1.77 million final week to scale up drug repurposing for inherited metabolic ailments via the Bio Protocol Launchpad. This milestone is driving cutting-edge research aimed toward creating the primary remedy for AARS2 Deficiency, a probably deadly uncommon genetic illness with no accredited therapies presently in the marketplace.
Curetopia’s modern strategy empowers sufferers and researchers to crowdfund medical breakthroughs, emphasizing neighborhood involvement and a shared stake within the ensuing developments. Over 1,000 particular person contributors participated on this $1.77 million elevate, highlighting the ability of community-driven science. Individuals in Curetopia’s decentralized medical trials turn out to be lively stakeholders within the therapies they assist to develop.
A key consequence of this effort is the identification of two drug repurposing candidates for AARS2 Deficiency, uncovered by a completely de-risked, high-throughput, yeast-powered screening course of. Curetopia is submitting a provisional patent for this discovery, working with two pioneer AARS2 households on launching parallel N-of-1 research, and plans to reinvest any future proceeds into additional research initiatives.
Dr. Ethan Perlstein, founder and CEO of Curetopia, said:
“The success of Curetopia’s auction in the face of brutal market conditions speaks to the fact that rare disease communities and crypto communities are natural allies. We’ve already demonstrated with the inaugural AARS2 program that we can deliver results on a timeline and with capital efficiency that is unheard of in TradBio. Now it’s time to cook.”
Curetopia is a part of the rising Decentralized Science (DeSci) motion, which has collectively raised over $15 million for research prior to now three months. This inflow of funding is well timed, as conventional sources just like the NIH and NSF face ongoing funds pressures.
Transferring ahead, Curetopia will develop an AI-driven, decentralized medical trial mannequin to handle 1000’s of uncommon ailments—every representing a $150 million market alternative based mostly on historic gross sales of Precedence Assessment Vouchers. By specializing in drug repurposing, the group seeks to expedite regulatory processes and ship life-changing remedies to sufferers extra shortly.
About Curetopia
Curetopia is a non-profit affiliation pioneering the world’s first Biotech DAO devoted to eradicating uncommon ailments via decentralized science launched by way of the Bio Protocol launchpad. With over 10,000 uncommon ailments affecting 1 in 10 individuals worldwide, Curetopia gives affected person communities with modern instruments to fund research, drive innovation, and guarantee promising therapies are usually not deserted.
Bio Protocol is a brand new monetary layer for early-stage biotech, accelerating the commercialization of breakthrough research. It allows international communities—sufferers, researchers, and crypto customers—to fund and co-own biotech improvements from day one. Backed by Binance Labs, Northpond Ventures, and 1kx, Bio has facilitated over $50M in research funding worldwide.